Press & Publications

Categories

“Biopharma returns to MC4R for drugs targeting genetic obesity as well as appetite loss.” Featured Story on Endpoints News by Kyle LaHucik

Published August 2025

Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity

Published August 2025

Superluminal Medicines Announces a Selective, Biased, MC4R Agonist is Advancing to IND-enabling Studies for the Treatment of Obesity

Published August 2025

Optimizing Drug Design by Merging Generative AI With Active Learning Frameworks: Published in Communications Chemistry

Published August 2025

Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship

Published June 2025

Superluminal Medicines Announces Formation of Scientific Advisory Board

Published September 2024

Superluminal Medicines Closes $120 Million Series A Round

Published September 2024

Superluminal Medicines Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics

Published August 2023